<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01607450</url>
  </required_header>
  <id_info>
    <org_study_id>1010002497</org_study_id>
    <secondary_id>R21HL092799</secondary_id>
    <nct_id>NCT01607450</nct_id>
  </id_info>
  <brief_title>Modulation of Human Myocardial Metabolism by GLP-1 Dose Response</brief_title>
  <official_title>Modulation of Human Myocardial Metabolism by GLP-1 Dose Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this proposal is to provide quantitative dose-response data for effects of
      GLP-1 on myocardial glucose uptake in healthy control subjects and obese type 2 diabetic
      subjects, in support of the design of later studies evaluating therapeutic applications of
      GLP-1 to heart disease.

      Aim 1: To measure the effects of GLP-1 infusion on myocardial fuel selection in lean healthy
      humans under fasting (fatty acid-dominant) conditions. Four groups of 10 lean healthy
      subjects will be studied during infusions of 0 (saline control), 0.5, 1.5, and 4.0
      pmol/kg/min GLP-1 (one study per subject). Cardiac metabolism will be measured using PET,
      using a dual-tracer approach which allows measurement of myocardial glucose uptake (the
      primary endpoint) along with total oxidation rate and myocardial perfusion (secondary
      endpoints). In concert with measures of circulating metabolites and regulatory hormones, the
      investigators will produce the most comprehensive assessment of actions of GLP-1 on
      myocardial metabolism in humans to date. Effects of each dose will be compared to the saline
      control, plus the investigators will combine all data and use nonlinear curve-fitting to
      derive sensitivity (ED50) and maximal responses for GLP-1 effects on myocardial glucose
      uptake.

      Aim 2: To measure the effects of GLP-1 infusion on myocardial fuel selection in obese type 2
      diabetic humans under fasting (fatty acid-dominant) conditions Four groups of 10 obese type 2
      diabetic subjects will be studied during infusions of 0, 0.5, 1.5, and 4.0 pmol/kg/min GLP-1
      as under Aim 1. Analyses will be parallel to those described under Aim 1. Results from Aims 1
      and 2 will be combined to allow direct comparison of the dose-response between nondiabetic
      control and type 2 diabetic subjects.

      No literature has been published to inform dose selection in the design of clinical trials of
      GLP-1 for modulation of heart fuel selection. With our expertise and experience in PET
      measurement of heart metabolism in diabetes, the investigators are uniquely positioned to
      fill this gap in knowledge. These studies are a necessary preamble to further evaluation of
      the potential for GLP-1 based treatments in heart disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial Glucose Uptake.</measure>
    <time_frame>After 12 hours of glucagon-like peptide 1 (GLP-1) exposure</time_frame>
    <description>Myocardial glucose uptake measured using 18FDG PET, quantified using a 3-compartment model with a lumped constant of 1.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial Blood Flow</measure>
    <time_frame>After 12 hours of GLP-1 exposure</time_frame>
    <description>Myocardial perfusion derived from acetate kinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Total Oxidation Rate</measure>
    <time_frame>After 12 hours of GLP-1 exposure</time_frame>
    <description>MVO2 derived from acetate kinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Index</measure>
    <time_frame>After 12 hours of GLP-1 exposure</time_frame>
    <description>Impedance cardiography-derived measurement of cardiac index, assessed following 12 hour exposure to treatment condition concurrent with the PET measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLP-1 Concentrations</measure>
    <time_frame>After 12 hours of GLP-1 exposure</time_frame>
    <description>Achieved GLP-1 concentrations at the end of the 12 hour treatment exposure</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>12 hour saline (control) infusion prior to PET study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-1 Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-1 Mid-Range Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-1 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLP-1 High Dose: 4.0 pmol/kg/min for 12 hours prior to PET study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1 Low Dose</intervention_name>
    <description>0.5mmol/kg/hr GLP-1 for 12 hours prior to PET study</description>
    <arm_group_label>GLP-1 Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1 Mid-Range Dose</intervention_name>
    <description>1.5mmol/kg/min for 12 hours prior to PET study</description>
    <arm_group_label>GLP-1 Mid-Range Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1 High Dose</intervention_name>
    <description>4.0mmol/kg/min GLP-1 for 12 hours prior to PET study</description>
    <arm_group_label>GLP-1 High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Normal saline placebo infusion for 12 hours prior to PET study</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-60

          -  Lean subjects will be defined as having a BMI &lt;25 kg/m2, in good general health,
             taking no regular medications

          -  Diabetic subjects will be obese (BMI &gt;30 kg/m2 but &lt;40 kg/m2), HbA1c 7.0-10.0%,
             treated with diet and exercise plus oral agents or injected insulin. All diabetic
             subjects will be treated with injected insulin for 2 weeks prior to study, to avoid
             potential confounding effects of other antidiabetic agents.

        Exclusion Criteria:

          -  Chronic illnesses or infections (other than type 2 diabetes)

          -  Known coronary artery disease or abnormal ECG on screening evaluation

          -  Blood pressure &gt; 160/100 mmHg on two occasions during screening evaluations. Current
             use of 3 or fewer blood pressure medications with blood pressure below this cutpoint
             will be acceptable.

          -  Total cholesterol &gt; 240 mg/dL. Current use of 2 or fewer lipid lowering agents with
             cholesterol below this cutpoint will be acceptable.

          -  Diabetic subjects: Treatment with a GLP-1 agonist or DPP4 inhibitor within the past 6
             months

          -  Known intolerance to injected GLP-1 agonist

          -  Treatment with PPAR gamma agonists currently or within the past 6 months

          -  Recognized microvascular complications (retinopathy, nephropathy, neuropathy)

          -  Unwillingness or inability to use injected insulin for the purposes of this study

          -  Chronic pain or other physical conditions which limit ability to remain supine for the
             duration of the study protocol

          -  History of claustrophobia, musculoskeletal or other factors which would result in an
             inability to comfortably remain within PET scanner gantry for the duration of the
             imaging protocol

          -  Occupational, investigational or other known radiation exposure which, together with
             the planned radiologic studies, will result in greater than 500 mrem total exposure in
             a contiguous 12 month period

          -  For female participants, current pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kieren J Mather, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana Clinical Research Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2012</study_first_submitted>
  <study_first_submitted_qc>May 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2012</study_first_posted>
  <results_first_submitted>November 16, 2015</results_first_submitted>
  <results_first_submitted_qc>January 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 17, 2016</results_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>lean healthy control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lean Placebo</title>
          <description>12 hour placebo (saline) infusion prior to PET study
Placebo: Saline placebo infusion for 12 hours prior to PET study</description>
        </group>
        <group group_id="P2">
          <title>Lean GLP-1 Mid-Range Dose</title>
          <description>GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study</description>
        </group>
        <group group_id="P3">
          <title>Type 2 DM GLP-1 Mid-Range Dose</title>
          <description>GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study</description>
        </group>
        <group group_id="P4">
          <title>Lean GLP-1 Low Dose</title>
          <description>GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study</description>
        </group>
        <group group_id="P5">
          <title>Type 2 DM GLP-1 Low Dose</title>
          <description>GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study</description>
        </group>
        <group group_id="P6">
          <title>Lean GLP-1 High Dose</title>
          <description>GLP-1 High Dose: 4.0 pmol/kg/min for 12 hours prior to PET study</description>
        </group>
        <group group_id="P7">
          <title>Type 2 DM GLP-1 High Dose</title>
          <description>GLP-1 High Dose: 1.5 pmol/kg/min for 12 hours prior to PET study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lean Saline</title>
          <description>12 hour placebo (saline) infusion prior to PET study
Placebo: Saline placebo infusion for 12 hours prior to PET study</description>
        </group>
        <group group_id="B2">
          <title>Lean GLP-1 0.5 Pmol/kg/Min</title>
          <description>GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study</description>
        </group>
        <group group_id="B3">
          <title>Type 2 DM GLP-1 0.5 Pmol/kg/Min</title>
          <description>GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study</description>
        </group>
        <group group_id="B4">
          <title>Lean GLP-1 1.5 Pmol/kg/Min</title>
          <description>GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study</description>
        </group>
        <group group_id="B5">
          <title>Type 2 DM GLP-1 1.5 Pmol/kg/Min</title>
          <description>GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study</description>
        </group>
        <group group_id="B6">
          <title>Lean GLP-1 4.0 Pmol/kg/Min</title>
          <description>GLP-1 High Dose:4.0 pmol/kg/min for 12 hours prior to PET study</description>
        </group>
        <group group_id="B7">
          <title>Type 2 DM GLP-1 4.0 Pmol/kg/Min</title>
          <description>GLP-1 High Dose:4.0 pmol/kg/min for 12 hours prior to PET study</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="7"/>
            <count group_id="B6" value="0"/>
            <count group_id="B7" value="0"/>
            <count group_id="B8" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.5" spread="10.6"/>
                    <measurement group_id="B2" value="38.0" spread="6.0"/>
                    <measurement group_id="B3" value="42" spread="0"/>
                    <measurement group_id="B4" value="46.0" spread="5.8"/>
                    <measurement group_id="B5" value="45.1" spread="7.9"/>
                    <measurement group_id="B8" value="42.7" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B8" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B8" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B8" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (kg/m2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.9" spread="1.6"/>
                    <measurement group_id="B2" value="23.0" spread="1.5"/>
                    <measurement group_id="B3" value="31.0" spread="0"/>
                    <measurement group_id="B4" value="22.9" spread="1.8"/>
                    <measurement group_id="B5" value="30.3" spread="1.7"/>
                    <measurement group_id="B8" value="25.7" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c (%)</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.47" spread="0.40"/>
                    <measurement group_id="B2" value="5.47" spread="0.40"/>
                    <measurement group_id="B3" value="7.0" spread="0"/>
                    <measurement group_id="B4" value="5.56" spread="0.34"/>
                    <measurement group_id="B5" value="8.40" spread="3.02"/>
                    <measurement group_id="B8" value="6.48" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Myocardial Glucose Uptake.</title>
        <description>Myocardial glucose uptake measured using 18FDG PET, quantified using a 3-compartment model with a lumped constant of 1.0.</description>
        <time_frame>After 12 hours of glucagon-like peptide 1 (GLP-1) exposure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lean Saline</title>
            <description>12 hour placebo (saline) infusion prior to PET study
Placebo: Saline placebo infusion for 12 hours prior to PET study</description>
          </group>
          <group group_id="O2">
            <title>Lean GLP-1 Low Dose</title>
            <description>GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O3">
            <title>Type 2 DM GLP-1 Low Dose</title>
            <description>GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O4">
            <title>Lean GLP-1 1.5 Pmol/kg/Min</title>
            <description>GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O5">
            <title>Type 2DM GLP-1 1.5 Pmol/kg/Min</title>
            <description>GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O6">
            <title>Lean GLP-1 High Dose</title>
            <description>GLP-1 High Dose: 4.0 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O7">
            <title>Type 2 DM GLP-1 High Dose</title>
            <description>GLP-1 High Dose: 4.0 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Glucose Uptake.</title>
          <description>Myocardial glucose uptake measured using 18FDG PET, quantified using a 3-compartment model with a lumped constant of 1.0.</description>
          <units>umol/min/100g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.46" spread="8.49"/>
                    <measurement group_id="O2" value="7.22" spread="9.26"/>
                    <measurement group_id="O3" value="0.05" spread="0"/>
                    <measurement group_id="O4" value="20.89" spread="12.47"/>
                    <measurement group_id="O5" value="5.57" spread="19.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Blood Flow</title>
        <description>Myocardial perfusion derived from acetate kinetics</description>
        <time_frame>After 12 hours of GLP-1 exposure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lean Saline</title>
            <description>12 hour placebo (saline) infusion prior to PET study
Placebo: Saline placebo infusion for 12 hours prior to PET study</description>
          </group>
          <group group_id="O2">
            <title>Lean GLP-1 Low Dose</title>
            <description>GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O3">
            <title>Type 2 DM GLP-1 Low Dose</title>
            <description>GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O4">
            <title>Lean GLP-1 1.5 Pmol/kg/Min</title>
            <description>GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O5">
            <title>Type 2DM GLP-1 1.5 Pmol/kg/Min</title>
            <description>GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O6">
            <title>Lean GLP-1 High Dose</title>
            <description>GLP-1 High Dose: 4.0 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O7">
            <title>Type 2 DM GLP-1 High Dose</title>
            <description>GLP-1 High Dose: 4.0 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Blood Flow</title>
          <description>Myocardial perfusion derived from acetate kinetics</description>
          <units>ml/min/100g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.66" spread="4.60"/>
                    <measurement group_id="O2" value="44.44" spread="9.17"/>
                    <measurement group_id="O3" value="47.61" spread="0"/>
                    <measurement group_id="O4" value="35.30" spread="7.35"/>
                    <measurement group_id="O5" value="51.19" spread="19.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Total Oxidation Rate</title>
        <description>MVO2 derived from acetate kinetics</description>
        <time_frame>After 12 hours of GLP-1 exposure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lean Saline</title>
            <description>12 hour placebo (saline) infusion prior to PET study
Placebo: Saline placebo infusion for 12 hours prior to PET study</description>
          </group>
          <group group_id="O2">
            <title>Lean GLP-1 Low Dose</title>
            <description>GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O3">
            <title>Type 2 DM GLP-1 Low Dose</title>
            <description>GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O4">
            <title>Lean GLP-1 1.5 Pmol/kg/Min</title>
            <description>GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O5">
            <title>Type 2DM GLP-1 1.5 Pmol/kg/Min</title>
            <description>GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O6">
            <title>Lean GLP-1 High Dose</title>
            <description>GLP-1 High Dose: 4.0 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O7">
            <title>Type 2 DM GLP-1 High Dose</title>
            <description>GLP-1 High Dose: 4.0 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Total Oxidation Rate</title>
          <description>MVO2 derived from acetate kinetics</description>
          <units>ml/min/100g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.25" spread="2.39"/>
                    <measurement group_id="O2" value="30.21" spread="14.32"/>
                    <measurement group_id="O3" value="65.30" spread="0"/>
                    <measurement group_id="O4" value="18.57" spread="3.78"/>
                    <measurement group_id="O5" value="59.85" spread="30.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Index</title>
        <description>Impedance cardiography-derived measurement of cardiac index, assessed following 12 hour exposure to treatment condition concurrent with the PET measurements.</description>
        <time_frame>After 12 hours of GLP-1 exposure</time_frame>
        <population>Analyses performed only on the groups with relevant primary outcome data observed</population>
        <group_list>
          <group group_id="O1">
            <title>Lean Saline</title>
            <description>12 hour placebo (saline) infusion prior to PET study
Placebo: Saline placebo infusion for 12 hours prior to PET study</description>
          </group>
          <group group_id="O2">
            <title>Lean GLP-1 0.5 Pmol/kg/Min</title>
            <description>GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O3">
            <title>Type 2 DM GLP-1 0.5 Pmol/kg/Min</title>
            <description>GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O4">
            <title>Lean GLP-1 1.5 Pmol/kg/Min</title>
            <description>GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O5">
            <title>Type 2 DM GLP-1 1.5 Pmol/kg/Min</title>
            <description>GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O6">
            <title>Lean GLP-1 4.0 Pmol/kg/Min</title>
            <description>GLP-1 High Dose:4.0 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O7">
            <title>Type 2 DM GLP-1 4.0 Pmol/kg/Min</title>
            <description>GLP-1 High Dose:4.0 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Index</title>
          <description>Impedance cardiography-derived measurement of cardiac index, assessed following 12 hour exposure to treatment condition concurrent with the PET measurements.</description>
          <population>Analyses performed only on the groups with relevant primary outcome data observed</population>
          <units>L/min/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="0.52"/>
                    <measurement group_id="O4" value="2.88" spread="0.31"/>
                    <measurement group_id="O5" value="2.90" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GLP-1 Concentrations</title>
        <description>Achieved GLP-1 concentrations at the end of the 12 hour treatment exposure</description>
        <time_frame>After 12 hours of GLP-1 exposure</time_frame>
        <population>Analyses performed only on the groups with relevant primary outcome data observed</population>
        <group_list>
          <group group_id="O1">
            <title>Lean Saline</title>
            <description>12 hour placebo (saline) infusion prior to PET study
Placebo: Saline placebo infusion for 12 hours prior to PET study</description>
          </group>
          <group group_id="O2">
            <title>Lean GLP-1 0.5 Pmol/kg/Min</title>
            <description>GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O3">
            <title>Type 2 DM GLP-1 0.5 Pmol/kg/Min</title>
            <description>GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O4">
            <title>Lean GLP-1 1.5 Pmol/kg/Min</title>
            <description>GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O5">
            <title>Type 2 DM GLP-1 1.5 Pmol/kg/Min</title>
            <description>GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O6">
            <title>Lean GLP-1 4.0 Pmol/kg/Min</title>
            <description>GLP-1 High Dose:4.0 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
          <group group_id="O7">
            <title>Type 2 DM GLP-1 4.0 Pmol/kg/Min</title>
            <description>GLP-1 High Dose:4.0 pmol/kg/min for 12 hours prior to PET study</description>
          </group>
        </group_list>
        <measure>
          <title>GLP-1 Concentrations</title>
          <description>Achieved GLP-1 concentrations at the end of the 12 hour treatment exposure</description>
          <population>Analyses performed only on the groups with relevant primary outcome data observed</population>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" spread="33.5"/>
                    <measurement group_id="O4" value="302.1" spread="149.1"/>
                    <measurement group_id="O5" value="307.8" spread="86.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lean Saline</title>
          <description>12 hour placebo (saline) infusion prior to PET study
Placebo: Saline placebo infusion for 12 hours prior to PET study</description>
        </group>
        <group group_id="E2">
          <title>Lean GLP-1 0.5 Pmol/kg/Min</title>
          <description>GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study</description>
        </group>
        <group group_id="E3">
          <title>Type 2 DM GLP-1 0.5 Pmol/kg/Min</title>
          <description>GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study</description>
        </group>
        <group group_id="E4">
          <title>Lean GLP-1 1.5 Pmol/kg/Min</title>
          <description>GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study</description>
        </group>
        <group group_id="E5">
          <title>Type 2 DM GLP-1 1.5 Pmol/kg/Min</title>
          <description>GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study</description>
        </group>
        <group group_id="E6">
          <title>Lean GLP-1 4.0 Pmol/kg/Min</title>
          <description>GLP-1 High Dose: 4.0 pmol/kg/min for 12 hours prior to PET study</description>
        </group>
        <group group_id="E7">
          <title>Type 2 DM GLP-1 4.0 Pmol/kg/Min</title>
          <description>GLP-1 High Dose: 4.0 pmol/kg/min for 12 hours prior to PET study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea associated with the infusion of GLP-1</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a dose-finding study of myocardial responses to systemically infused GLP-1. After ascertaining no detectable response in controls with low dose, we completed mid dose studies. Finding an important difference there we did not do the high dose</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kieren J Mather MD FRCPC</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-278-7826</phone>
      <email>kmather@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

